Form 4: CytomX Therapeutics Director Mani Mohindru Granted 38,000 Stock Options

CytomX Therapeutics, Inc. director Mani Mohindru was granted 38,000 stock options with an exercise price of $2.82, vesting on the earlier of the first anniversary of the grant date or the 2026 Annual Meeting.

Summary

• Mani Mohindru, a Director of CytomX Therapeutics, Inc. (CTMX), was granted 38,000 stock options.
• The options have an exercise price of $2.82 per share.
• The grant date for these options was June 11, 2025.
• The options will vest and become exercisable as to 100% of the total number of shares on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, contingent on continuous service as a director.
• The expiration date for these options is June 10, 2035.
• Following this transaction, Mani Mohindru directly beneficially owns 38,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a standard, expected compensation event (stock option grant) for a director. It's neither overwhelmingly positive nor negative, but rather a neutral, routine disclosure that aligns director incentives with shareholder value over time.

Positives

• Granting of stock options to a director aligns the director's interests with those of shareholders, as the options gain value if the stock price increases above the exercise price.
• The vesting schedule encourages long-term commitment and continuous service from the director.

Negatives

• The exercise price of $2.82 is the current market price at the time of grant (implied by a $0 price for the derivative itself), meaning the options only have intrinsic value if the stock price rises above this level.

Risks

• The value of the stock options is entirely dependent on the future performance of CytomX Therapeutics' stock price; if the stock price does not exceed $2.82, the options may expire worthless.
• The vesting is contingent on continuous service, meaning the director must remain with the company to realize the benefit.

Future Outlook

The document primarily reports a past transaction (a grant on a future date, which is common for Form 4 filings that report grants effective on a specific date, even if that date is in the future relative to the filing date). It implies a future commitment from the director due to the vesting schedule tied to continuous service and future events like the 2026 Annual Meeting.

Industry Context

Stock option grants are a standard form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align interests with shareholders. This grant to a director of CytomX Therapeutics is consistent with typical compensation practices in the sector.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to attract and retain talent and align incentives.
• The exercise price being at the money ($2.82) is standard for incentive stock option grants, meaning the options only gain value if the company's stock price appreciates from the grant date.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is also a typical structure for director equity awards, promoting continued board service.

Related Party Transactions

• The stock option grant to a director is a related party transaction, but it's a standard, disclosed compensation event rather than an unusual dealing.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholders, as the options gain value only if the stock price increases, potentially encouraging decisions that benefit stock performance.
• Employees: No direct impact on employees is mentioned.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or the date of the 2026 Annual Meeting of CytomX Therapeutics' stockholders, assuming continuous service.
• Mani Mohindru may exercise the options at any time after vesting and before the expiration date of June 10, 2035, provided the stock price is above the exercise price of $2.82.

Key Dates

Keywords

CytomX Therapeutics, CTMX, Stock Option Grant, Mani Mohindru, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Biotechnology, Pharmaceuticals